{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:44:40Z","timestamp":1775097880454,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Roche Molecular Systems, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40121-026-01325-4","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T08:09:38Z","timestamp":1773562178000},"page":"1137-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Real-World Data to Support Claim Expansion of the Cobas SARS-CoV-2 Test in Asymptomatic Testing: Data from the National Football League Occupational Surveillance Program"],"prefix":"10.1007","volume":"15","author":[{"given":"Baiyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin B.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akos","family":"Somoskovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Jarem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Volkir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Baumfeld Andre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"1325_CR1","unstructured":"World Health Organization. WHO COVID-19 dashboard. https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=o&m49=840. Accessed September 22, 2025."},{"key":"1325_CR2","unstructured":"Centers for Disease Control. Surveillance and data analytics. https:\/\/www.cdc.gov\/covid\/php\/surveillance\/index.html. Accessed September 22, 2025."},{"key":"1325_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJMp2213920","volume":"388","author":"WM El-Sadr","year":"2023","unstructured":"El-Sadr WM, Vasan A, El-Mohandes A. Facing the new Covid-19 reality. N Engl J Med. 2023;388:385\u20137. https:\/\/doi.org\/10.1056\/NEJMp2213920.","journal-title":"N Engl J Med"},{"key":"1325_CR4","unstructured":"U.S. Food & Drug Administration. Cobas SARS-CoV-2. https:\/\/www.fda.gov\/media\/136046\/download?attachment. Accessed September 22, 2025."},{"key":"1325_CR5","unstructured":"Centers for Disease Control. Infection control guidance: SARS-CoV-2. https:\/\/www.cdc.gov\/covid\/hcp\/infection-control\/index.html. Accessed Spetember 22, 2025."},{"key":"1325_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmi.2022.01.007","volume":"28","author":"E Carrara","year":"2022","unstructured":"Carrara E, Ong DSY, Hussein K, et al. ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the health care setting. Clin Microbiol Infect. 2022;28:672\u201380. https:\/\/doi.org\/10.1016\/j.cmi.2022.01.007.","journal-title":"Clin Microbiol Infect"},{"key":"1325_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115513","volume":"102","author":"S Antonara","year":"2022","unstructured":"Antonara S, Ozbolt P, Landon L, et al. Detection of SARS-CoV-2 infection in asymptomatic populations using the DiaSorin molecular Simplexa and Roche Cobas EUA assays. Diagn Microbiol Infect Dis. 2022;102:115513. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115513.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1325_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/ajcp\/aqab173","volume":"157","author":"P Drain","year":"2022","unstructured":"Drain P, Sulaiman R, Hoppers M, et al. Performance of the LumiraDx microfluidic immunofluorescence point-of-care SARS-CoV-2 antigen test in asymptomatic adults and children. Am J Clin Pathol. 2022;157:602\u20137. https:\/\/doi.org\/10.1093\/ajcp\/aqab173.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"1325_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9070868","volume":"9","author":"M Ifko","year":"2021","unstructured":"Ifko M, Skvarc M. Use of immunochromatographic SARS-CoV-2 antigen testing in eight long-term care facilities for the elderly. Healthcare. 2021;9(7):868.","journal-title":"Healthcare"},{"key":"1325_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1001\/jamainternmed.2021.2114","volume":"181","author":"CD Mack","year":"2021","unstructured":"Mack CD, DiFiori J, Tai CG, et al. SARS-CoV-2 transmission risk among National Basketball Association players, staff, and vendors exposed to individuals with positive test results after COVID-19 recovery during the 2020 regular and postseason. JAMA Intern Med. 2021;181:960\u20136. https:\/\/doi.org\/10.1001\/jamainternmed.2021.2114.","journal-title":"JAMA Intern Med"},{"key":"1325_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jama.2022.9479","volume":"328","author":"CG Tai","year":"2022","unstructured":"Tai CG, Maragakis LL, Connolly S, et al. Association between COVID-19 booster vaccination and Omicron infection in a highly vaccinated cohort of players and staff in the National Basketball Association. JAMA. 2022;328:209\u201311. https:\/\/doi.org\/10.1001\/jama.2022.9479.","journal-title":"JAMA"},{"key":"1325_CR12","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7108a4","author":"C Mack","year":"2022","unstructured":"Mack C, Wasserman E, Killerby M, et al. Results from a test-to-release from isolation strategy among fully vaccinated National Football League players and staff members with COVID-19\u2014United States, December 14\u201319, 2021. MMWR Morb Mortal Wkly Rep. 2022. https:\/\/doi.org\/10.15585\/mmwr.mm7108a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1325_CR13","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7004e2","author":"C Mack","year":"2021","unstructured":"Mack C, Wasserman E, Killerby M, et al. Implementation and evolution of mitigation measures, testing, and contact tracing in the National Football League, August 9\u2013November 21, 2020. MMWR Morb Mortal Wkly Rep. 2021. https:\/\/doi.org\/10.15585\/mmwr.mm7004e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1325_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.7326\/M21-0319","volume":"174","author":"CD Mack","year":"2021","unstructured":"Mack CD, Osterholm M, Wasserman EB, et al. Optimizing SARS-CoV-2 surveillance in the United States: insights from the National Football League occupational health program. Ann Intern Med. 2021;174:1081\u20139. https:\/\/doi.org\/10.7326\/M21-0319.","journal-title":"Ann Intern Med"},{"key":"1325_CR15","unstructured":"U.S. Food & Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices. https:\/\/www.fda.gov\/files\/medical%20devices\/published\/Use-of-Real-World-Evidence-to-Support-Regulatory-Decision-Making-for-Medical-Devices---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf."},{"key":"1325_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/M23-0385","volume":"176","author":"A Soni","year":"2023","unstructured":"Soni A, Herbert C, Lin H, et al. Performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection. Ann Intern Med. 2023;176:975\u201382. https:\/\/doi.org\/10.7326\/M23-0385.","journal-title":"Ann Intern Med"},{"key":"1325_CR17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm695152a3","author":"IW Pray","year":"2021","unstructured":"Pray IW, Ford L, Cole D, et al. Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses\u2014Wisconsin, September\u2013October 2020. MMWR Morb Mortal Wkly Rep. 2021. https:\/\/doi.org\/10.15585\/mmwr.mm695152a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1325_CR18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7003e3","author":"JL Prince-Guerra","year":"2021","unstructured":"Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites\u2014Pima County, Arizona, November 3\u201317, 2020. MMWR Morb Mortal Wkly Rep. 2021. https:\/\/doi.org\/10.15585\/mmwr.mm7003e3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1325_CR19","unstructured":"R Core Team. R installation and administration. https:\/\/cran.r-project.org\/doc\/manuals\/r-patched\/R-admin.html."},{"key":"1325_CR20","unstructured":"SAS\u00ae. SAS\u00ae Enterprise Guide\u00ae 8.2: User\u2019s guide. https:\/\/documentation.sas.com\/api\/docsets\/egug\/8.2\/content\/egug.pdf?locale=en. Accessed Spetember 22, 2025."},{"key":"1325_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209\u201312. https:\/\/doi.org\/10.1080\/01621459.1927.10502953.","journal-title":"J Am Stat Assoc"},{"key":"1325_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/2168479018763591","volume":"52","author":"NA Dreyer","year":"2018","unstructured":"Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Ther Innov Regul Sci. 2018;52:362\u20138. https:\/\/doi.org\/10.1177\/2168479018763591.","journal-title":"Ther Innov Regul Sci"},{"key":"1325_CR23","unstructured":"U.S. Food & Drug Administration. Examples of real-world evidence (RWE) used in medical device regulatory decisions. https:\/\/www.fda.gov\/media\/146258\/download. Accessed 2025 Sept 22."},{"key":"1325_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000001416","author":"MJ Lopez","year":"2022","unstructured":"Lopez MJ, Mack C, Bliss T, et al. Observed versus expected COVID-19 infections among National Football League players during the 2020 season. Epidemiology. 2022. https:\/\/doi.org\/10.1097\/EDE.0000000000001416.","journal-title":"Epidemiology"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01325-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:50:23Z","timestamp":1775094623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01325-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01325-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Baiyu Yang and Elodie Baumfeld Andre were employees of Roche Molecular Systems at the time of this study and hold shares in F Hoffmann-La Roche. Erin B. Wasserman is a full-time employee of IQVIA. Akos Somoskovi, Daniel Jarem, and Patrick Volkir are full-time employees of Roche Molecular Systems and hold shares in F Hoffmann-La Roche. Christina Mack is a full-time employee of IQVIA and holds stock in IQVIA, AstraZeneca, Johnson & Johnson and MindMed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This analysis was conducted in accordance with applicable regulations. As the data used were from an occupational monitoring program (as opposed to a research study), no separate IRB submission was required and individuals were not required to provide written, informed consent. Both the NFL and the NFLPA approved the submission of the master data file to the FDA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"COBAS is a trademark of Roche. All other product names and trademarks are the property of their respective owners.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}